FLT3 and acute myeloid leukemia: The best FLT3 inhibitor use in the frontline setting is also not clear, and randomized studies comparing intensive chemotherapy plus midostaurin to either gilteritinib (NCT04027309) or crenolanib (NCT03258931) in younger, fit patients with newly diagnosed FLT3-mutated AML are ongoing.